Skinvisible, Inc. (SKVI), Quoin Pharmaceuticals Pr
Post# of 47
(Total Views: 485)
Posted On: 02/05/2018 4:37:08 PM
Skinvisible, Inc. (SKVI), Quoin Pharmaceuticals Proposed Merger to Address Opioid Pain Management Market
-A merger between Skinvisible and Quoin will enable a successful entry on the post-surgical pain management market
- Opioids – which typically refer to oxycodone, hydrocodone, and fentanyl – are highly addictive painkillers; nearly three in 10 Americans prescribed opioids for chronic pain will abuse them
- Opioids are becoming increasingly deadly to Americans; in 2016, two-thirds of drug-related deaths involved opioids; in fact, since 1999, opioid-related deaths in the United States have increased nearly fourfold
- Drug abuse is a burden shared by every state; nearly 63,600 Americans lost their lives to drug overdoses in 2016 – a 21 percent increase over the previous year; from 2000 to 2016, the U.S. Centers for Disease Control and Prevention estimates that more than 600,000 people died from drug overdoses in the United States
- Every 25 minutes, a baby in the United States is born suffering from opioid withdrawal
Skinvisible, Inc. (OTCQB: SKVI) previously announced the signing of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed this year, and the resulting entity will operate under the name Quoin Pharmaceuticals Inc. and will continue to trade on the OTCQB market.
Quoin’s strength is within the area of pharmaceutical product development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product delivery and performance.
Quoin’s lead product is QRX001 – a transdermal NMDA receptor antagonist for the effective treatment of pain following surgery. QRX001 delivers up to 72 hours of effective pain relief after surgical interventions. Almost 30 clinical studies have been performed to date on the NMDA receptor antagonist, clearly showing that sub-anesthetic doses reduced 24-hour PCA morphine consumption; reduced post-operative nausea and vomiting; reduced pain intensity; resulted in adverse events that were mild or absent; and generated better results than any other single product or combination. The aim of the product is to also reduce the use of opioids for pain management following an operation.
Upon the product’s launch, QRX001 is expected to provide surgeons with a new and effective alternative to opioids. Opioid abuse has reached an epidemic level in the U.S., with opioid overdoses causing more than 90 deaths per day (http://nnw.fm/V60zK). This number has grown exponentially in the past decade, according to the Centers for Disease Control and Prevention, with opioid use remaining widespread despite the risks. Today, approximately 12 million Americans report that they use pain killers in a non-medicinal way.
The opioid market in the U.S. is estimated at $6 billion annually. With the opioid epidemic now deemed a National Health Emergency, there is a significant push to find new products that reduce or eliminate their use, particularly in a post-surgical setting, which is where 50 percent of people who become addicted first become exposed to these drugs.
In addition to wrecking lives, opioid abuse poses a massive burden on the economy. Adding up money lost from costs related to health care, addiction treatment, reduced work productivity and crime, the Centers for Disease Control and Prevention estimates that the economic burden of the opioid crisis is more than $78.5 billion per year.
Almost half of the victims were first introduced to opioids after undergoing surgery. According to the National Center for Health Statistics, 100 million surgeries take place in the U.S. every year (http://nnw.fm/8fdOl). At least 50 million of these surgical interventions necessitate the use of post-operative pain management pharmaceuticals.
Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even further. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.
The Skinvisible announcement states that new technologies and product synergies between the two companies could potentially provide significant value to shareholders after the merger. Together, Skinvisible and Quoin could maximize their product development opportunities, as noted by Skinvisible President Terry Howlett. The official news release also included a disclaimer regarding ‘forward looking’ statements.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
-A merger between Skinvisible and Quoin will enable a successful entry on the post-surgical pain management market
- Opioids – which typically refer to oxycodone, hydrocodone, and fentanyl – are highly addictive painkillers; nearly three in 10 Americans prescribed opioids for chronic pain will abuse them
- Opioids are becoming increasingly deadly to Americans; in 2016, two-thirds of drug-related deaths involved opioids; in fact, since 1999, opioid-related deaths in the United States have increased nearly fourfold
- Drug abuse is a burden shared by every state; nearly 63,600 Americans lost their lives to drug overdoses in 2016 – a 21 percent increase over the previous year; from 2000 to 2016, the U.S. Centers for Disease Control and Prevention estimates that more than 600,000 people died from drug overdoses in the United States
- Every 25 minutes, a baby in the United States is born suffering from opioid withdrawal
Skinvisible, Inc. (OTCQB: SKVI) previously announced the signing of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed this year, and the resulting entity will operate under the name Quoin Pharmaceuticals Inc. and will continue to trade on the OTCQB market.
Quoin’s strength is within the area of pharmaceutical product development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product delivery and performance.
Quoin’s lead product is QRX001 – a transdermal NMDA receptor antagonist for the effective treatment of pain following surgery. QRX001 delivers up to 72 hours of effective pain relief after surgical interventions. Almost 30 clinical studies have been performed to date on the NMDA receptor antagonist, clearly showing that sub-anesthetic doses reduced 24-hour PCA morphine consumption; reduced post-operative nausea and vomiting; reduced pain intensity; resulted in adverse events that were mild or absent; and generated better results than any other single product or combination. The aim of the product is to also reduce the use of opioids for pain management following an operation.
Upon the product’s launch, QRX001 is expected to provide surgeons with a new and effective alternative to opioids. Opioid abuse has reached an epidemic level in the U.S., with opioid overdoses causing more than 90 deaths per day (http://nnw.fm/V60zK). This number has grown exponentially in the past decade, according to the Centers for Disease Control and Prevention, with opioid use remaining widespread despite the risks. Today, approximately 12 million Americans report that they use pain killers in a non-medicinal way.
The opioid market in the U.S. is estimated at $6 billion annually. With the opioid epidemic now deemed a National Health Emergency, there is a significant push to find new products that reduce or eliminate their use, particularly in a post-surgical setting, which is where 50 percent of people who become addicted first become exposed to these drugs.
In addition to wrecking lives, opioid abuse poses a massive burden on the economy. Adding up money lost from costs related to health care, addiction treatment, reduced work productivity and crime, the Centers for Disease Control and Prevention estimates that the economic burden of the opioid crisis is more than $78.5 billion per year.
Almost half of the victims were first introduced to opioids after undergoing surgery. According to the National Center for Health Statistics, 100 million surgeries take place in the U.S. every year (http://nnw.fm/8fdOl). At least 50 million of these surgical interventions necessitate the use of post-operative pain management pharmaceuticals.
Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even further. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.
The Skinvisible announcement states that new technologies and product synergies between the two companies could potentially provide significant value to shareholders after the merger. Together, Skinvisible and Quoin could maximize their product development opportunities, as noted by Skinvisible President Terry Howlett. The official news release also included a disclaimer regarding ‘forward looking’ statements.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)